SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 3, 2017
Date of Report
(Date of Earliest Event Reported)
CHINA BIOTECH HOLDINGS LIMITED
(Exact Name of Registrant as Specified in its Charter)
AGATE ISLAND ACQUISITION CORPORATION
(Former Name of Registrant as Specified in its Charter)
Delaware 000-55631 81-2310905
(State or other (Commission File Number) (IRS Employer
jurisdiction Identification No.)
of incorporation)
China Biotech Company Corporation
17700 Castleton Street, Suite 583
City of Industry, California 91748
(Address of principal executive offices) (zip code)
(011) 86 1851 838 8462
(Registrant's telephone number, including area code
215 Apolena Avenue
Newport Beach, California 92662
(Former Address of Principal Executive Offices)
ITEM 3.02 Unregistered Sales of Equity Securities
On May 4, 2017, Agate Island Acquisition Corporation (the "Registrant"
or the "Company") issued 10,000,000 shares of its common stock pursuant
to Section 4(2) of the Securities Act of 1933 at par representing 94.1%
of the total outstanding 8,500,000 shares of common stock as follows:
Tingting Chang 8,000,000
With the issuance of the stock and the redemption of 19,500,000 shares
of stock (discussed below), the Company effected a change in its control and
the new majority shareholder(s) elected new management of the Company. The
Company may develop its business plan by future acquisitions or mergers but
no agreements have been reached regarding any acquisition or other business
combination. The Company changed its name as part of the change in control.
If the Company makes any acquisitions, mergers or other business combination,
the Company will file a Form 8-K but until such time the Company remains a
shell company.
ITEM 5.01 Changes in Control of Registrant
On May 3, 2017, the following events occurred which resulted in a
change of control of the Registrant:
1. The Registrant cancelled an aggregate of 19,500,000 of the then
20,000,000 shares of outstanding stock valued at par.
2. The then current officers and directors resigned.
3. New officer(s) and director(s) were appointed and elected.
The disclosure required by Item 5.01(a)(8) of Form 8-K was previously
filed with the Securities and Exchange Commission on Form 10-12G filed on
August 9, 2016 as amended and supplemented by the information contained
in this report.
The Registrant has been formed to concentrate on the research, development
and sale of health products to promote resistence to Alzheimer's disease and
elderly mental degradation and to assist cerebrovascular patient treatment
and recovery. The Registrant intends to primarily focus on the health
benefits that can be, and have been, derived from Acer Truncatum, a unique
tree species native to China. The Registrant intends to develop seed oil
from the tree that contains 6% nervonic acid for use in further medical
research and as an additive to certain food products such as tea, spices and
protein drinks to promote mental health and prevention of brain disease such
as Alzheimer's, Parkinson's and aging degradation.
ITEM 5.02 Departure of Directors or Principal Officers;
Election of Directors
On May 3, 2017, the following events occurred:
James M. Cassidy resigned as the Registrant's president, secretary
and director.
James McKillop resigned as the Registrant's vice president and
irector.
Tingting Chang was named Chief Executive Officer, Secretary and Chief
Financial Officer of the Registrant.
Tingting Chang serves as CEO, Secretary, Chief Financial Officer and sole
director of the Registrant. Since 2013 to the present, Mr. Tingting worked at
Beijing Acer Truncatum Century Agriculture Science Technology Co. From 2013 to
2016 he served as sales manager responsible for planning, implementing and
directing the sales activities of the company including developing strategic
plans, budget preparation and coordination of the sales teams. From 2016 to the
present Mrs. Chang has served as CEO responsible for setting strategy and
direction, modeling and setting the company's culture and values, leading and
training the senior executive and allocating capital. In 2013, Mr. Tingting
received a MSC degree in Technology and Innovation Management from Sussex
University, the United Kingdom and in 2012 received a Bachelor of Arts degree
in Product Design.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunder duly authorized.
CHINA BIOTECH HOLDINGS LIMITED
Date: May 4, 2017 /s/ Tingting Chang
Chief Executive Officer
